crimeancongo
hemorrhag
fever
cchf
viral
infect
seen
asia
europ
middl
east
high
mortal
rate
cchf
caus
viru
genu
nairoviru
famili
bunyavirida
mortal
rate
vari
accord
geograph
area
viru
usual
transmit
human
tick
bite
direct
contact
blood
infect
person
acut
phase
diseas
accord
world
health
organ
cchf
seen
countri
case
report
annual
four
countri
includ
turkey
tropic
climat
zone
gradual
expand
impact
global
warm
enlarg
geograph
area
cover
tick
spread
diseas
pathogenesi
diseas
divid
three
phase
prehemorrhag
phase
hemorrhag
phase
convalesc
phase
transmiss
viru
replic
spread
bloodstream
caus
flulik
symptom
last
week
prehemorrhag
phase
stage
viral
replic
decreas
macrophagederiv
cytokin
caus
macrophag
activ
syndrom
hemorrhag
phase
second
phase
death
may
occur
due
hemophagocytosi
dissemin
intravascular
coagul
dic
disord
hemostasi
import
featur
cchf
dic
thought
occur
via
three
mechan
increas
releas
tissu
factor
direct
injuri
releas
proinflammatori
mediat
increas
synthesi
cell
surfac
tissu
factor
activ
extrins
coagul
pathway
direct
injuri
effect
endothelium
platelet
occur
proinflammatori
mediat
releas
virusinfect
monocyt
lead
destruct
endotheli
cell
platelet
dic
present
decreas
clot
factor
platelet
addit
liver
dysfunct
occur
cours
diseas
contribut
decreas
coagul
factor
result
event
massiv
bleed
occur
cchf
although
main
treatment
option
cchf
support
therapi
ribavirin
inhibit
viral
replic
vivo
shown
reduc
death
murin
model
ribavirin
guanosin
analog
broadspectrum
antivir
activ
recent
studi
support
use
ribavirin
cchf
retrospect
small
number
case
import
clinic
question
emerg
due
increas
number
patient
countri
also
ribavirin
therapi
evalu
treatment
cchf
ribavirin
antivir
drug
use
cchf
effect
remain
controversi
although
studi
suggest
use
ribavirin
effect
cchf
other
suggest
opposit
wellknown
studi
ribavirin
treatment
conduct
iran
mardani
et
al
crimeancongo
hemorrhag
fever
cchf
viral
infect
associ
high
mortal
rate
ribavirin
drug
use
treatment
diseas
studi
investig
effect
ribavirin
cchf
retrospect
date
includ
small
number
case
recent
year
due
climat
chang
number
case
cchf
turkey
increas
experi
treatment
cchf
improv
sever
studi
evalu
efficaci
ribavirin
turkey
includ
one
random
control
trial
two
studi
larg
number
case
studi
ribavirin
therapi
shown
decreas
mortal
rate
mortal
rate
patient
treat
ribavirin
treat
drug
find
suggest
patient
cchf
follow
support
care
random
control
trial
larger
group
conduct
intern
societi
infecti
diseas
publish
elsevi
ltd
right
reserv
studi
eight
patient
treat
ribavirin
die
seven
patient
treat
ribavirin
die
differ
statist
signific
howev
small
number
case
control
group
retrospect
design
studi
may
decreas
reliabl
result
mortal
rate
report
mardani
et
al
higher
turkey
cchf
strain
turkey
differ
iran
vivo
studi
shown
differ
cchf
viru
strain
respond
differ
ribavirin
may
explain
patient
respond
well
ribavirin
therapi
iran
contrast
studi
iran
ribavirin
therapi
shown
decreas
mortal
rate
turkey
studi
mortal
rate
patient
treat
ribavirin
patient
treat
ribavirin
differ
term
mortal
length
hospit
stay
transfus
blood
product
among
patient
treat
treat
ribavirin
studi
effect
ribavirin
cchf
retrospect
includ
case
therefor
determin
effect
ribavirin
cchf
problemat
one
random
control
trial
evalu
efficaci
ribavirin
perform
turkey
studi
compar
patient
given
ribavirin
without
treatment
signific
differ
mortal
rate
proport
patient
requir
platelet
transfus
length
hospit
stay
recoveri
time
laboratori
paramet
sinc
first
case
report
turkey
number
case
cchf
increas
steadili
two
studi
larg
number
case
show
chang
cours
diseas
ribavirin
treatment
four
hundr
patient
cchf
confirm
pcr
treat
support
therapi
twenti
patient
die
mortal
rate
similar
studi
ribavirin
treatment
cchf
turkey
anoth
studi
mortal
rate
patient
take
ribavirin
compar
patient
without
treatment
p
studi
suggest
ribavirin
effect
treatment
cchf
howev
research
consid
ribavirin
effect
especi
administ
earli
period
diseas
give
ribavirin
patient
earli
late
period
diseas
produc
differ
result
one
studi
includ
larg
number
case
mortal
rate
patient
start
ribavirin
within
first
day
onset
symptom
differ
patient
start
treatment
later
anoth
studi
turkey
one
patient
treat
first
day
onset
symptom
die
compar
two
patient
treat
day
onset
symptom
differ
signific
anoth
studi
initi
ribavirin
first
day
onset
symptom
compar
start
treatment
later
shown
reduc
mortal
rate
p
studi
mortal
rate
patient
receiv
ribavirin
bleed
lower
patient
receiv
ribavirin
later
respect
p
report
ribavirin
effect
first
period
diseas
also
conclud
decreas
viral
replic
first
week
reduc
mortal
rate
hypothesi
support
fact
viral
load
import
factor
contribut
mortal
cchf
howev
studi
turkey
contradict
hypothesi
studi
patient
given
ribavirin
treat
support
therapi
first
day
treatment
viral
load
declin
mortal
rate
similar
two
group
cchf
viral
load
import
determin
mortal
rate
ribavirin
shown
decreas
viral
load
analysi
studi
turkey
shown
gradual
decreas
use
ribavirin
despit
mortal
rate
chang
significantli
respect
tabl
find
indic
ineffect
ribavirin
although
efficaci
ribavirin
cchf
highli
controversi
use
justifi
base
drug
avail
howev
seriou
side
effect
major
obstacl
becom
recommend
one
studi
patient
given
ribavirin
patient
without
treatment
follow
mortal
rate
differ
howev
first
day
consid
mortal
rate
time
higher
receiv
ribavirin
increas
mortal
studi
relat
toxic
effect
ribavirin
patient
poor
clinic
cours
ribavirin
increas
mortal
rate
due
sever
organ
damag
similarli
sever
acut
respiratori
syndrom
sar
patient
sever
hypoxemia
treat
ribavirin
higher
mortal
rate
due
effect
drug
anoth
obstacl
use
ribavirin
genotox
effect
ribavirin
shown
mutagen
effect
lymphocyt
sperm
find
suggest
patient
cchf
follow
support
care
random
control
trial
includ
larger
popul
conduct
